These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502 [TBL] [Abstract][Full Text] [Related]
9. CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. Wei G; Zhang Y; Zhao H; Wang Y; Liu Y; Liang B; Wang X; Xu H; Cui J; Wu W; Zhao K; Nagler A; Chang AH; Hu Y; Huang H Cancer Immunol Res; 2021 Sep; 9(9):1061-1070. PubMed ID: 34290048 [TBL] [Abstract][Full Text] [Related]
10. CAR T-cell therapy for B-cell lymphoma. Denlinger N; Bond D; Jaglowski S Curr Probl Cancer; 2022 Feb; 46(1):100826. PubMed ID: 35012754 [TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions. Benevolo Savelli C; Clerico M; Botto B; Secreto C; Cavallo F; Dellacasa C; Busca A; Bruno B; Freilone R; Cerrano M; Novo M Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201473 [TBL] [Abstract][Full Text] [Related]
12. Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas. Ding S; Mao X; Cao Y; Wang N; Xu H; Zhou J Target Oncol; 2020 Jun; 15(3):365-375. PubMed ID: 32495161 [TBL] [Abstract][Full Text] [Related]
13. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review. Du J; Zhang Y J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815 [TBL] [Abstract][Full Text] [Related]
14. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas. Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y Front Immunol; 2020; 11():564099. PubMed ID: 33329526 [TBL] [Abstract][Full Text] [Related]
15. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
16. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407 [TBL] [Abstract][Full Text] [Related]